AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country, The Financial Times’ Eleanor Olcott and Hannah Kuchler reported on Friday. The company appointed new executives to lead its Chinese oncology business, which has come under intense scrutiny over two incidents including alleged illegal sales practices for cancer drugs. Alex Lin is replacing Michael Lai as country general manager and has promoted Mary Guan, who was previously at its Chinese general medicines unit, to lead oncology in China, according to people with direct knowledge of the matter.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Datroway Approved for Advanced Breast Cancer in the US
- AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
- Novo Nordisk’s (NYSE:NVO) Ozempic and Wegovy Lined Up for Medicare Drug Price Negotiations
- Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
- AstraZeneca price target raised to 13,100 GBp from 12,600 GBp at Guggenheim